One year of growth hormone treatment in adults with prader-willi syndrome improves body composition: Results from a randomized, placebo-controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 11, 2010, Pages 4943-4950

  Sode Carlsen, Rasmus ^a   Farholt, Stense ^a   Rabben, Kai Fr ^b   Bollerslev, Jens ^c   Schreiner, Thomas ^c   Jurik, Anne Grethe ^a   Christiansen, Jens Sandahl ^a   Höybye, Charlotte ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Frambu   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ABDOMEN; ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EVENING DOSAGE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HEADACHE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MALE; MUSCLE MASS; NAUSEA; PHYSICAL PERFORMANCE; PRADER WILLI SYNDROME; PRETIBIAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THIGH; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WALKING;

EID: 78049503047     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0907     Document Type: Article

References (28)

1. Gunay-Aygun M, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB 2001 The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 108:E92
2. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F 1993 Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91:398-402
3. Burman P, Ritzén EM, Lindgren AC 2001 Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 22:787-799 (Pubitemid 34214295)
4. Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, Chiumello G 1997 Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr 65:1369-1374
5. Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, Hajnal JV, Howard JK, Holland A, Bloom SR 2001 Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 86:4330-4338
6. Höybye C, Hilding A, Jacobsson H, Thorén M 2002 Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 87:3590-3597
7. Theodoro MF, Talebizadeh Z, Butler MG 2006 Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity (Silver Spring) 14:1685-1690
8. van Mil EG, Westerterp KR, Kester AD, Curfs LM, Gerver WJ, Schrander-Stumpel CT, Saris WH 2000 Activity related energy expenditure in children and adolescents with Prader-Willi syndrome. Int J Obes Relat Metab Disord 24:429-434
9. Vestergaard P, Kristensen K, Bruun JM, Østergaard JR, Heickendorff L, Mosekilde L, Richelsen B 2004 Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index-a cross-sectional study. J Pediatr 144:614-619
10. Goldstone AP 2004 Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 15:12-20 (Pubitemid 38198094)
11. Binnerts A, Swart GR, Wilson JH, Hoogerbrugge N, Pols HA, Birkenhager JC, Lamberts SW 1992 The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf) 37:79-87
12. Salomon F, Cuneo RC, Hesp R, Sönksen PH 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797-1803
13. Gondoni LA, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G 2008 Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. J Endocrinol Invest 31:765-772
14. Hoybye C, Hilding A, Jacobsson H, Thoren M 2003 Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 58:653-661
15. Mogul HR, Lee PD, Whitman BY, Zipf WB, Frey M, Myers S, Cahan M, Pinyerd B, Southren AL 2008 Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab 93:1238-1245
16. Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C 2010 Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Horm IGF Res 20:179-184
17. American Diabetes Association 2006 Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl 1):S43-S48
18. Frystyk J, Dinesen B, Orskov H 1995 Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 5:169-176
19. Albareda M, Rodríguez-Espinosa J, Murugo M, de Leiva A, Corcoy R 2000 Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43:1507-1511
20. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M 1998 Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47:1643-1649
21. Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Sandahl Christiansen J, Höybye C 2009 Assessment of physical function in adults with Prader-Willi syndrome. Disabil Rehabil 31:1780-1784
22. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ 2007 Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39-48 (Pubitemid 47016245)
23. Beauregard C, Utz AL, Schaub AE, Nachtigall L, Biller BM, Miller KK, Klibanski A 2008 Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:2063-2071
24. Marzullo P, Marcassa C, Campini R, Eleuteri E, Minocci A, Sartorio A, Vettor R, Liuzzi A, Grugni G 2007 Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab 92:1364-1371
25. Butler MG, Theodoro MF, Bittel DC, Donnelly JE 2007 Energy expenditure and physical activity in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet A 143:449-459
26. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Moller J, Muller J, Skakkebaek NE, Christiansen JS 1991 Long-term growth hormone treatment in growth hormone deficient adults. Acta Endocrinol (Copenh) 125:449-453
27. Bollerslev J, Ueland T, Jørgensen AP, Fougner KJ, Wergeland R, Schreiner T, Burman P 2006 Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154:537-543
28. Colao A, di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G 2002 The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 87:1088-1093